Systemic disease treatments are used to prolong survival and improve quality of life. Single-agent sequential cytotoxic therapy is preferred in the setting of metastatic breast cancer. Combination cytotoxic therapy is associated with a higher response rate, but toxicities are also increased, and it confers no survival benefit. Chemotherapy is used in patients with resistance to endocrine therapy or ER/PR-negative disease and a moderate or high disease burden.
Discover highlights from ASCO 2021 on the management of metastatic breast cancer here.
Learn more about the treatment and management of metastatic breast cancer.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Fast Five Quiz: Are You Prepared to Confront Metastatic Breast Cancer? - Medscape - Dec 21, 2021.